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A B S T R A C T
A 49-year-old man was admitted with symptomatic, sustained monomorphic ventricular tachycardia.
He had a previous history of AMP-kinase disease associated with hypertrophic cardiomyopathy and
complete heart block, and a pre-existing dual chamber pacemaker. He also had a mechanical tricuspid
valve replacement and mitral valve replacement, for severe tricuspid regurgitation from right ventricle
(RV) lead-induced injury to the tricuspid valve and a ﬁbroblastoma on the mitral valve. His pre-existing
RV lead was maintained between the prosthetic valve annulus and the native annulus. Inability to place
an implantable cardioverter-deﬁbrillator (ICD) in the RV due to the presence of a mechanical tricuspid
valve replacement represented a rare but challenging clinical scenario. Surgical epicardial lead
placement or the use of a subcutaneous ICD (S-ICD) were possible alternatives. Traditional ICD lead
placement was favored because of the broad QRS from RV pacing meaning that use of the S-ICD was not
possible due to failure of the electrocardiogram to lie within the bounds of the screening template, and
the perceived high risk of repeat thoracotomy. We describe the technique for ICD lead placement in a
mid-lateral cardiac venous branch of the coronary sinus with the ability to deliver anti-tachycardia
pacing and cardiac resynchronization. To our knowledge this is the ﬁrst report of an ICD in the mid-
lateral cardiac vein, with cardiac resynchronization.
<Learning objective: This case describes the technique for implantable cardioverter-deﬁbrillator
placement in the coronary sinus with biventricular pacing in a patient with a mechanical tricuspid and
pre-existing right ventricular endocardial lead. This technique represents a viable alternative to repeat
thoracotomy and surgical lead placement, where the risks of complication, prolonged hospital stay and
lead failure are high. It also offers the ability to deliver anti-tachycardia pacing and cardiac
resynchronization.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Inability to place an implantable cardioverter-deﬁbrillator
(ICD) in the right ventricle (RV) due to the presence of a
mechanical tricuspid valve replacement represents a rare but
challenging clinical scenario. Surgical epicardial lead placement or
the use of a subcutaneous ICD (S-ICD) represent possible
alternatives. Previous case reports have documented placement
of an ICD lead in the middle branch of the coronary sinus [1], the
caval vein [2], and the azygous vein [3]. We report a case of ICD lead* Corresponding author at: The Heart Hospital, University College Hospital,
16–18 Westmoreland St, London W1G 8PH, UK. Tel.: +44 020 3765 8651;
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightplacement in a mid-lateral cardiac venous branch of the coronary
sinus (CS) with the ability to deliver anti-tachycardia pacing and
cardiac resynchronization.
Case report
A 49-year-old male was admitted with two episodes of
symptomatic sustained monomorphic ventricular tachycardia
(VT) (Fig. 1A), requiring direct current (DC) cardioversion. He
had a past history of AMP-kinase disease associated with
hypertrophic cardiomyopathy and complete heart block. Initially
an epicardial pacemaker was implanted and this was subsequently
upgraded to a dual chamber pacemaker. Due to the development of
permanent atrial ﬁbrillation with transient ischemic attacks,
anticoagulation therapy was initiated. In 2010, he underwent
mechanical tricuspid valve replacement (TVR) and mitral valves reserved.
Fig. 1.
(A) 12-lead electrocardiogram (ECG) of the patient’s monomorphic ventricular tachycardia (VT) on presentation. (B) Subsequent paced ECG showing paced QRS-
duration (QRSD) of 186 ms. (C) Selective angiography of the mid-lateral branch of the coronary sinus (CS) in the left anterior oblique (LAO) projection, with
mechanical tricuspid valve (TV) and mitral valve (MV) visible, along with pre-existing right ventricular (RV) lead. (D) LAO projection of the ﬁnal position of the
implantable cardioverter-deﬁbrillator coil in the mid-lateral branch of CS, with TV and MV visible, along with right ventricular (RV) lead and old epicardial leads.
(E) Bi-ventricular pacing at follow-up with QRSD 142 ms.
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lead-induced injury to the tricuspid valve and a ﬁbroblastoma on
the mitral valve. A 35 mm St Jude Medical1 (SJM; St. Jude Medical
Inc.; Minneapolis, MN) mechanical prosthesis was used in the
tricuspid position and the pre-existing RV lead was maintained
between the prosthetic valve annulus and the native annulus. At
the time of surgery, two previously placed epicardial leads and the
endovascular right atrial (RA) lead were removed, as he was now in
permanent atrial ﬁbrillation (AF). Echocardiography on admission
revealed an ejection fraction of 40%. Due to permanent RV pacing
his QRS duration was 186 ms (Fig. 1B).
A decision was made to implant an ICD lead in the coronary
sinus (CS) instead of a surgically placed epicardial lead to avoid the
risk of repeat surgery and the concern that epicardial leads are
unreliable and have limited longevity [4]. This option had the
advantage of being able to deliver anti-tachycardia pacing for VT
episodes as well as offering biventricular pacing, unlike the S-ICD.
Additionally, due to the permanent pacing with a broad QRS
interval, he failed the screening for S-ICD.
Left-arm venography conﬁrmed a patent left subclavian
system. Before re-opening the existing pacemaker pocket, the CS
was imaged by cannulating the right femoral vein using a ﬁxed
curve St Jude SL3 sheath and a steerable electrophysiology (EP)
catheter. CS venography demonstrated a large caliber mid-lateral
cardiac venous branch (Fig. 1C and Video 1). Following extraction
of the existing pacemaker and a single left axillary puncture, the
coronary sinus was re-cannulated with a steerable EP catheter and
a Boston Scientiﬁc Accuity Pro sheath (Natick, MA, USA) (Video 2).
Subsequently a Medtronic (Medtronic, Inc., Minneapolis, MN, USA)
sub-selection catheter was used to help intubate the mid lateral
coronary vein (Video 3). This sheath was then exchanged for an 11F
75 cm Mullins sheath (Medtronic, Inc., Minneapolis, MN, USA) overa 0.035 in guidewire. The hemostatic valve at the proximal end of
the Mullins sheath was cut off before introduction to allow it to be
split afterwards. Approximately 7 cm of the distal end of the sheath
was removed so that it was short enough to permit delivery of 9F
Medtronic Sprint-Quattro Secure S single coil 6935 ICD lead, as no
commercially available sheath was available for this purpose. The
lead was advanced to the distal portion of the mid-lateral cardiac
vein (Video 4) and the sheath split and removed (Video 5). Lead
parameters showed an impedance of 1292 V, with a sensed R wave
amplitude of 4.5 mV and a threshold of 2.25 V at 0.4 ms. Fig. 1D
shows the ﬁnal left anterior oblique view of the lead. Deﬁbrillation
threshold testing (DFT) was not initially performed, as the patient
had sub-therapeutic anticoagulation leading up to the procedure.
The device was subsequently programmed to ventricular rate
modulated pacing (VVIR) at 60/min, with a left ventricular (LV)
offset of 10 ms to promote biventricular pacing and QRS
narrowing. At follow-up, 12-Lead electrocardiogram (ECG) showed
narrowing of the QRS duration to 142 ms (Fig. 1E). A post-implant
device check revealed that the patient had had successful anti-
tachycardia pacing for further sustained VT and a DFT performed
when international normalized ratio was therapeutic and success-
ful with a single 25 J shock.
Supplementary videos related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jccase.2015.08.004.
Discussion
The presence of a tilting disk valve prosthesis is an absolute
contraindication to endocardial lead placement in view of the risk
of acute valve failure, damage to the lead, and death. Repeat
thoracotomy is associated with signiﬁcant risks, long hospital
stays, and a high lead failure rate [4]. The advantage of the
N.T. Srinivasan, O.R. Segal / Journal of Cardiology Cases 12 (2015) 180–182182approach used in the present case was that it is the only solution
that offers anti-tachycardia pacing and bi-ventricular pacing, in
addition to deﬁbrillation. Although S-ICD remains an alternative
option to endovascular lead placement, the broad QRS complexes
in the present case meant that the patient failed ECG screening for
S-ICD.
Several lead conﬁgurations have been described previously
including the use of a ﬂoating double-coil in the inferior vena cava
(IVC) [2], azygous vein ICD lead implant [3], the use of a CS
deﬁbrillation coil coupled with a left sided array [5], and placement
of the ICD lead in the low right atrium [6]. Azygous vein
implantation can be challenging technically and adequate
deﬁbrillation vectors are hard to achieve without an RV coil.
Similar issues can occur with ICD lead implantation at the low right
atrium and IVC. One option to negate the issue of inadequate ﬁeld
vector coverage is to tunnel the lead into the abdomen as
previously described by Cohen et al. [7] and place the ‘active can’ in
the abdomen, but this requires a more complex surgical procedure
under general anesthesia and again does not offer cardiac
resynchronization needed in our patient. The placement of a
left-sided array would have still required a lead in the CS, resulting
in longer procedure times and the risk of infection in a patient with
two metallic prosthetic valves. Additionally problems have been
reported with subcutaneous arrays such as lead dislocation and
lead insulation defects, which means that their use requires close
surveillance with regular chest radiographs and annual DFTs
[8]. Thus, in order to offer the combination of deﬁbrillation, anti-
tachycardia pacing, and cardiac resynchronization, we elected to
place a standard ICD lead in a lateral branch of the CS.
A technique for implantation of the ICD lead into the middle
cardiac vein has been previously described in a series of six
patients [1]. At a 5 year follow-up, there were no acute or late
complications and no lead displacements [1]. We utilized this
approach due to the evidence suggesting its effectiveness and
feasibility [1]. Additionally positioning the ICD coil in the inferior
epicardium of the LV wall increases the amount of myocardium
covered by the current ﬁeld and allows for greater deﬁbrillation
mass across the ventricle. In animal studies, CS ICD electrodes have
been shown to have a lower deﬁbrillation threshold than
conventional ICD placement [9]. Finally this approach enabled
us to deliver biventricular pacing to our patient and anti-
tachycardia pacing (ATP), without the need for two separate leads
in the CS as previously described [1]. This has potential advantages
with regard to complications relating to thrombosis and ﬁbrosis
within the CS and mortality associated with possible future lead
removal.
This case describes a novel technique for delivery of an ICD lead
into the mid-lateral branch of the CS which permits the use of ATP
and deﬁbrillation, as well as cardiac resynchronization through
biventricular pacing using an LV lead site on the mid-lateral LV
wall. In such cases, standard tools for CS cannulation are not
suitable as the deﬁbrillating lead is bigger than standard CS leads.
We therefore used a Mullins sheath that was available in our
institution. It should be noted that other options exist, such as the
use of the WorleyTM system (9Fr) (Merit Medical Systems, Inc.,
South Jordan, UT, USA) or a smaller deﬁbrillating lead (DurataTM
(SJM; St. Jude Medical Inc.; Minneapolis, MN), RiataTM (SJM; St.
Jude Medical Inc.; Minneapolis, MN), Sprint-FidelisTM(Medtronic,
Inc., Minneapolis, MN, USA), Reliance 4-FrontTM (Boston Scientiﬁc,
Inc., Natick, MA, USA)), depending on their availability in different
centers. In our center, we no longer carry 7F ICD leads routinely andtherefore elected to insert a standard 9F lead instead. Although
more difﬁcult to position in smaller coronary veins, 9F leads are
theoretically more stable once positioned due to their size and
weight. Additionally, given the well-documented concerns regard-
ing premature failure and longevity of 7F leads such as the St Jude
Riata and Medtronic Sprint-Fidelis leads [10,11], we elected to use
the 9F Medtronic Sprint-Quattro lead, which has excellent
longevity data [11]. An important decision-making choice is
whether or not to deploy the helix within the CS. We did not deploy
the helix as sensing was already provided by the RV lead, lead
parameters with an un-deployed helix were acceptable and
importantly to minimize the risk of CS trauma and pericardial
tamponade. Although lead function is known to be improved with
helical deployment, we chose not to take this additional risk for the
above reasons. The long-term safety of a deﬁbrillating coil in a
coronary vein is unknown as well as the risk for later lead
extraction; however, initial case series results are promising
[1]. There is a need for new leads to be designed for this application
and to minimize ingrowth on the coil when placed in a venous
branch of the CS.
We believe this is the ﬁrst case to report placement of a CS ICD
lead in a lateral branch of the cardiac vein with the addition of
biventricular pacing. In cases where biventricular pacing is
preferred and an existing RV lead is in situ, placement of an ICD
lead into the lateral branches of the CS should be considered.
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